for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rockwell Medical Inc

RMTI.OQ

Latest Trade

2.39USD

Change

0.00(0.00%)

Volume

28,046

Today's Range

2.39

 - 

2.42

52 Week Range

2.19

 - 

6.88

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.39
Open
2.40
Volume
28,046
3M AVG Volume
6.66
Today's High
2.42
Today's Low
2.39
52 Week High
6.88
52 Week Low
2.19
Shares Out (MIL)
63.82
Market Cap (MIL)
160.20
Forward P/E
-3.72
Dividend (Yield %)
--

Next Event

Q3 2019 Rockwell Medical Inc Earnings Release

Latest Developments

More

Rockwell Medical Says Q2 Loss Per Share $0.18

Rockwell Medical Announces Acceptance By FDA Of New Drug Application For I.V. Triferic

Rockwell Medical Comments On Preliminary Proposed CMS Rule

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Rockwell Medical Inc

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company's drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.

Industry

Medical Equipment & Supplies

Contact Info

30142 S Wixom Rd

+1.248.9609009

http://www.rockwellmed.com

Executive Leadership

Benjamin Wolin

Independent Chairman of the Board

Stuart M. Paul

President, Chief Executive Officer, Director

Angus W. Smith

Chief Financial Officer

Jim McCarthy

Senior Vice President - Corporate and Business Development

Paul E. McGarry

Principal Accounting Officer, Vice President, Corporate Controller

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.390

2017

-0.510

2018

-0.610

2019(E)

-0.643
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.51
Price To Book (MRQ)
5.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.45
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-92.00
Return on Equity (TTM)
-67.65

Latest News

Latest News

BRIEF-Rockwell Medical Update On Calcitriol New Manufacturing Submission To FDA

* ROCKWELL MEDICAL UPDATE ON CALCITRIOL NEW MANUFACTURING SUBMISSION TO FDA

BRIEF-Rockwell Medical Reports Q4 Loss Per Share $0.18

* ROCKWELL MEDICAL REPORTS FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Rockwell Medical, Inc. Appoints Two Independent Executives To Board Of Directors

* ROCKWELL MEDICAL, INC. APPOINTS TWO INDEPENDENT AND EXPERIENCED LIFE SCIENCES EXECUTIVES TO BOARD OF DIRECTORS

BRIEF-Richmond Brothers Reports 10 Pct Stake In Rockwell Medical

* RICHMOND BROTHERS INC SAYS ON MARCH 7, RICHMOND BROTHERS AND RICHMOND ENTERED INTO LETTER AGREEMENT WITH ROCKWELL MEDICAL INC

BRIEF-Rockwell Medical Signs License Agreement With Quimica Europea To Commercialize Triferic In Peru

* ROCKWELL MEDICAL SIGNS EXCLUSIVE LICENSE AGREEMENT WITH QUIMICA EUROPEA TO COMMERCIALIZE TRIFERIC IN PERU

BRIEF-Richmond Brothers Says On Nov 22, Entered Into Settlement And Standstill Agreement With Rockwell Medical

* RICHMOND BROTHERS INC SAYS ON NOVEMBER 22, ENTERED INTO SETTLEMENT AND STANDSTILL AGREEMENT WITH ROCKWELL MEDICAL INC - SEC FILING

BRIEF-Rockwell Medical posts Q3 loss of $0.10 per share

* Q3 sales rose 14.1 percent to $14.6 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-ROCKWELL MEDICAL SAYS FDA REQUESTS EXTRA TIME TO REVIEW CALCITRIOL SUBMISSION

* ROCKWELL UPDATE ON CALCITRIOL POST-APPROVAL MANUFACTURING SUBMISSION TO FDA

BRIEF-Rockwell files Calcitriol post-approval manufacturing submission with FDA

* Rockwell files Calcitriol post-approval manufacturing submission with FDA

BRIEF-Rockwell Medical updates progress on calcitriol commercial launch

* Rockwell Medical updates progress on calcitriol commercial launch

BRIEF-‍Richmond Brothers responds to Rockwell Medical's board appointment

* Richmond Brothers Inc issues statement in response to Rockwell Medical Inc's appointment of John Cooper to its board of directors

BRIEF-Rockwell Medical appoints John Cooper to board

* Rockwell Medical appoints John G. Cooper to board of directors

BRIEF-Richmond Brothers and Mark H. Ravich issue statement on Rockwell Medical Inc

* Richmond Brothers - "Will not settle for anything less than real and meaningful changes" to Rockwell Medical Board Source text for Eikon: Further company coverage:

BRIEF-Richmond Brothers issues public letter to incumbent directors of Rockwell Medical

* Richmond Brothers Inc issues public letter to incumbent directors of Rockwell Medical Inc.

BRIEF-Rockwell Medical responds to Richmond Group

* Issued statement concerning Richmond Group's filing of an amended schedule 13D with Securities and Exchange Commission

BRIEF-‍Richmond Brothers Inc​ seeks immediate replacement of Rockwell Medical CEO Robert Chioini

* Richmond Brothers Inc says it intends to nominate a competing slate of director candidates for Rockwell Medical Inc

BRIEF-Rockwell Medical Q2 loss per share $0.14

* Q2 sales $13.2 million Source text for Eikon: Further company coverage:

BRIEF-Rockwell Medical, Baxter Healthcare settle arbitration

* Rockwell Medical Inc - on June 23, 2017, co and Baxter Healthcare Corporation settled the arbitration related to claims made by each party

Rockwell Medical shareholders back Ravich for board seat-sources

Shareholders of Rockwell Medical Inc. <RMTI.O> voted investor Mark Ravich onto the company's board of directors, according to people familiar with the matter.

BRIEF-Rockwell Medical says Richmond, Ravich each personally own less than 1 pct of co

* Co "clarifies that David Richmond and Mark Ravich each personally own less than 1% of Rockwell" Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up